GLMD (Galmed Pharmaceuticals) Debt-to-EBITDA : 0.00 (As of Mar. 2026)


GLMD Galmed Pharmaceuticals Ltd GLMD
29 GF Score
Price $0.55
! 2 Warning Signs
View Full Analysis

What is Galmed Pharmaceuticals Debt-to-EBITDA?

Galmed Pharmaceuticals GLMD +1.23% 29 Debt-to-EBITDA is 0.00 as of Mar. 2026. GuruFocus rates GLMD with a GF Score™ of 29/100. The stock has 2 warning signs investors should review. Among 291 Biotechnology companies, Galmed Pharmaceuticals ranks worse than 343642.27% on this metric.

Debt-to-EBITDA measures a company's ability to pay off its debt.

Galmed Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was $0.00 Mil. Galmed Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was $0.00 Mil. Galmed Pharmaceuticals's annualized EBITDA for the quarter that ended in Mar. 2026 was $-8.18 Mil. Galmed Pharmaceuticals's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2026 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Galmed Pharmaceuticals's Debt-to-EBITDA or its related term are showing as below:

GLMD's Debt-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 1.14
* Ranked among companies with meaningful Debt-to-EBITDA only.

Galmed Pharmaceuticals  (NAS:GLMD) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Galmed Pharmaceuticals Debt-to-EBITDA Related Terms

Galmed Pharmaceuticals Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Galmed Pharmaceuticals's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Galmed Pharmaceuticals Debt-to-EBITDA Chart

Galmed Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.01 -0.01 -0.01 0.00 0.00

Galmed Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

GLMD vs FBLG, SXTP, CELZ: Debt-to-EBITDA Comparison

For the Biotechnology subindustry, Galmed Pharmaceuticals's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Galmed Pharmaceuticals Debt-to-EBITDA vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galmed Pharmaceuticals's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Galmed Pharmaceuticals's Debt-to-EBITDA falls into.


GLMD
29GF Score
Galmed Pharmaceuticals Ltd GLMD
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Galmed Pharmaceuticals Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Galmed Pharmaceuticals's Debt-to-EBITDA for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -8.51
=0.00

Galmed Pharmaceuticals's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2026 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -8.176
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.

Frequently Asked Questions Learn more about Debt-to-EBITDA →
What does a Debt-to-EBITDA of 0.00 mean?
Galmed Pharmaceuticals (GLMD) has a Debt-to-EBITDA of 0.00 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Galmed Pharmaceuticals. According to the industry distribution chart, Galmed Pharmaceuticals ranks #999999 out of 291 companies in the Biotechnology industry.
Is Galmed Pharmaceuticals' Debt-to-EBITDA too high?
Galmed Pharmaceuticals' current Debt-to-EBITDA is 0.00. Based on the distribution chart, Galmed Pharmaceuticals ranks #999999 out of 291 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Galmed Pharmaceuticals has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Galmed Pharmaceuticals' Debt-to-EBITDA compare to FBLG and SXTP?
According to the Biotechnology industry distribution chart, Galmed Pharmaceuticals ranks #999999 out of 291 companies for Debt-to-EBITDA. This places Galmed Pharmaceuticals in the lower half of its industry. The industry median Debt-to-EBITDA is 1.14. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.14, based on 291 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Galmed Pharmaceuticals. For the Biotechnology industry, the median Debt-to-EBITDA is 1.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Galmed Pharmaceuticals's current Debt-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galmed Pharmaceuticals stock overvalued right now?
Galmed Pharmaceuticals (GLMD) has a current Debt-to-EBITDA of 0.00. The current Debt-to-EBITDA is 0.00. Galmed Pharmaceuticals' overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Galmed Pharmaceuticals (GLMD), the current Debt-to-EBITDA is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Galmed Pharmaceuticals Business Description

Address c/o Meitar Law Offices, 16 Abba Hillel Road, Ramat Gan, ISR, 5250608
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. The company focuses on the development of Aramchol for combination therapy for GI oncological indications. The company is actively pursuing opportunities in the biotech and medtech spaces to expand and diversify its product pipeline targeting GI, cardiometabolic indications and other product candidates.
29GF Score

Get the complete analysis for GLMD

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.55
Price